(-)-(S)-N2-(tert-butoxycarbonyl)-N1-(2,6-dimethylphenyl)alaninamide | 86516-39-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (-)-(S)-N2-(tert-butoxycarbonyl)-N1-(2,6-dimethylphenyl)alaninamide
• 英文别名: (-)-(S)-N²-(tert-butoxycarbonyl)-N¹-(2,6-dimethylphenyl)alaninamide；tert-butyl (2S)-(1-((2,6-dimethylphenyl)amino)-1-oxopropan-2-yl)carbamate
• CAS: 86516-39-4
• 化学式: C₁₆H₂₄N₂O₃
• 分子量: 292.378
• InChiKey: ZZRLCIVRQJCXQB-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.16
• 重原子数：
  21.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.43
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (-)-(S)-N2-(tert-butoxycarbonyl)-N1-(2,6-dimethylphenyl)alaninamide 在 盐酸 、 barium dihydroxide 作用下， 以 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 (2S)-2-amino-N-(2,6-dimethylphenyl)-N-methylpropanamide;hydrochloride
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Chiral α-Aminoanilides with Central Antinociceptive Activity

  摘要：

  Tocainide and related optically active chiral alpha-aminoanilides were synthesized and tested in vivo via the hot plate test to evaluate their central analgesic action. The aims of the study were to verify if a) the increase in lipophilicity, obtained by the introduction of an alkyl group on the steric center (3f-i), and the replacement of the C=O group with the C=S (10) group as well as the introduction of a methyl or ethyl group on the amidic nitrogen atom (8a-c) would produce an increase in central analgesic efficacy with respect to Tocainide; b) the 2,6-xylidide moiety is crucial for high analgesic activity (3b-e); c) the hydrogen atom bonded to the amidic nitrogen moiety is an essential pharmacophoric element for analgesic activity. Among all the synthesized compounds, 3f showed antinociceptive properties with a good enantioselective index.

  DOI：

  10.1021/jm061078e
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 N-甲基吗啉 、 sodium hydroxide 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.25h， 生成 (-)-(S)-N2-(tert-butoxycarbonyl)-N1-(2,6-dimethylphenyl)alaninamide
  参考文献：
  名称：

  Synthesis and Anticonvulsant Activity of Some 2/3-Benzoylaminopropionanilide Derivatives

  摘要：

  在本研究中，描述了十六种2/3-苯甲酰氨基丙酰胺衍生物的合成及其抗癫痫活性。这些化合物的分子设计基于拉科酰胺的结构修饰，拉科酰胺是一种具有新型抗癫痫活性的功能化氨基酸。通过光谱和分析数据确认了这些化合物的结构。合成化合物的抗癫痫活性通过最大电休克（MES）和皮下美特拉唑（scMet）癫痫测试确定，而它们的神经毒性则使用滚筒测试进行检测。所有这些测试均按照抗癫痫药物开发（ADD）计划的程序进行。大多数化合物在MES或scMet筛选测试中有效。根据滚筒测试，在研究剂量下，没有任何化合物显示出神经毒性。系列中最有效的化合物是3、12和13，它们分别在N-苯环上带有2-甲基、2-乙基和2-异丙基取代基。

  DOI：

  10.1055/s-0032-1308982

文献信息

• Amine Activation:<i>N</i>-Arylamino Acid Amide Synthesis from Isothioureas and Amino Acids
  作者：Yan-Ping Zhu、Pieter Mampuys、Sergey Sergeyev、Steven Ballet、Bert U. W. Maes

  DOI：10.1002/adsc.201700134

  日期：2017.7.17

  functional group compatibility, with respect to side chain functionality of the amino acid (e. g. aliphatic and aromatic OH, (hetero)aromatic NH, amide NH, thioether), and the chiral amino acids do not undergo epimerization. The mechanism of the new amide synthesis has been studied.

  Ñ -arylamino酰胺已经通过基于新方法被合成ñ -芳基胺活化成异硫脲，随后用下铁催化氨基酸反应。可以使用三组分反应与市售试剂叔丁基异氰化物和S-苯基苯硫代磺酸盐轻松地制备活化的N-芳基胺。相对于氨基酸（例如脂族和芳族OH，（杂）芳族NH，酰胺NH，硫醚）的侧链官能度，该方案显示出广泛的官能团相容性，并且手性氨基酸不发生差向异构化。已经研究了新酰胺合成的机理。
• Constrained TRPV1 agonists synthesized via silver-mediated intramolecular azo-methine ylide cycloaddition of α-iminoamides
  作者：Thomas O. Painter、Krisztian Kaszas、Jacklyn Gross、Justin T. Douglas、Victor W. Day、Michael J. Iadarola、Conrad Santini

  DOI：10.1016/j.bmcl.2013.12.061

  日期：2014.2

  As part of an effort to identify agonists of TRPV1, a peripheral sensory nerve ion channel, high throughput screening of the NIH Small Molecule Repository (SMR) collection identified MLS002174161, a pentacyclic benzodiazepine. A synthesis effort was initiated that ultimately afforded racemic seco analogs 12 of the SMR compound via a silver mediated intramolecular [3+2] cycloaddition of an azo-methine ylide generated from alpha-iminoamides 11. The cycloaddition set four contiguous stereocenters and, in some cases, also spontaneously afforded imides 13 from 12. The synthesis of compounds 12, the features that facilitated the conversion of 12-13, and their partial agonist activity against TRPV1 are discussed. (C) 2013 Elsevier Ltd. All rights reserved.